<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04836884</url>
  </required_header>
  <id_info>
    <org_study_id>20-011265</org_study_id>
    <nct_id>NCT04836884</nct_id>
  </id_info>
  <brief_title>Vascular Anomaly Pathology and Genomics Biopsy Study</brief_title>
  <official_title>Validation of Core Biopsy of Vascular Anomalies for Clinical Pathology and Genomics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to gather information on the safety and effectiveness of core&#xD;
      biopsy of vascular anomalies for clinical pathology and clinical genomics studies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vascular anomalies or vascular malformations often are treated with minimally invasive&#xD;
      sclerotherapy, embolization or ablation based on clinical and imaging features without&#xD;
      acquisition of tissue. Over the last two decades there have been significant advancements in&#xD;
      the understanding of the genetic basis for various vascular anomalies/malformations, which&#xD;
      may guide use of therapies for individualized treatment.&#xD;
&#xD;
      As such, given the emergence of novel medications for treatment of vascular&#xD;
      anomalies/malformations based on genetic information, acquisition of tissue for pathology and&#xD;
      genomic characterization will be increasingly important as treatment of vascular&#xD;
      anomalies/vascular malformations moves toward individualized medicine approach.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 6, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adequacy of core biopsy of vascular anomalies for clinical genomics studies</measure>
    <time_frame>18 months</time_frame>
    <description>DNA and RNA will be extracted from the biopsy specimens, undergo qualitative/quantitative quality control assessment and be analyzed by whole genome sequencing (DNA) and RNA sequence analysis (RNA-seq) to determine the adequacy of vascular anomaly biopsy for vascular anomaly genomics characterization.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adequacy of core biopsy of vascular anomalies for clinical pathology evaluation</measure>
    <time_frame>18 months</time_frame>
    <description>Tissue from the vascular anomaly biopsies will undergo histopathology and immunohistochemical staining to determine the adequacy of vascular anomaly core biopsy for clinical pathology characterization.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of vascular anomaly core biopsy</measure>
    <time_frame>30 days</time_frame>
    <description>Number of participants with biopsy-related adverse events as assessed by CTCAE v4.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Vascular Malformations</condition>
  <condition>Vascular Anomaly</condition>
  <condition>Hemangioma</condition>
  <condition>Arteriovenous Malformations</condition>
  <condition>Venous Malformation</condition>
  <condition>Klippel Trenaunay Syndrome</condition>
  <condition>Lymphatic Malformation</condition>
  <arm_group>
    <arm_group_label>Vascular anomaly/malformation biopsy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with a vascular anomaly will have a research percutaneous vascular anomaly/malformation biopsy completed at the time of the clinically indicated percutaneous sclerotherapy, embolization and/or ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Vascular Anomaly/Malformation Biopsy</intervention_name>
    <description>US-guided percutaneous vascular anomaly core needle biopsy of up to 10 cores using an 18-gauge co-axial core needle biopsy device at the time of clinically indicated sclerotherapy, embolization or ablation treatment.</description>
    <arm_group_label>Vascular anomaly/malformation biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with a clinical and imaging diagnosis of a vascular anomaly.&#xD;
&#xD;
          -  No prior treatment for the vascular anomaly.&#xD;
&#xD;
          -  Subjects undergoing clinically indicated sclerotherapy, embolization and/or ablation.&#xD;
&#xD;
          -  Male or female with age greater than or equal to 18 years.&#xD;
&#xD;
          -  Capacity and willingness to provide a written informed consent..&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with prior treatment for their vascular anomaly.&#xD;
&#xD;
          -  Uncorrectable coagulopathy.&#xD;
&#xD;
          -  Pregnant and/or breast-feeding subjects. A negative pregnancy test within 48 hours of&#xD;
             the procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily Bendel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David A Woodrum, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Desirae Howe-Clayton</last_name>
    <phone>507-255-0111</phone>
    <email>Howe.Desirae@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Scott Thompson, MD, PhD</last_name>
    <phone>507-284-2511</phone>
    <email>Thompson.Scott@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 25, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 19, 2021</last_update_submitted>
  <last_update_submitted_qc>April 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Emily C. Bendel, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemangioma</mesh_term>
    <mesh_term>Lymphangioma</mesh_term>
    <mesh_term>Arteriovenous Malformations</mesh_term>
    <mesh_term>Vascular Malformations</mesh_term>
    <mesh_term>Klippel-Trenaunay-Weber Syndrome</mesh_term>
    <mesh_term>Lymphatic Abnormalities</mesh_term>
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

